论文部分内容阅读
2012年诺贝尔生理与医学奖颁发给Shinya Yamanaka和Sir John Gurdon后,受此风潮影响,医学领域对诱导性多功能干细胞(iPS)和重编程技术的关注激增。当iPS被认为极有可能开启细胞治疗和再生医学一个新时代时,基于iPS的细胞治疗应用于临床前首当其冲的是安全相关问题。在这篇综述中,笔者概述了iPS来源的神经干/祖细胞在脊髓损伤(SCI)的临床前研究以及其体内安全性问题,并试图讨论其临床应用策略。
Following the wave of 2012 Nobel Prize in Physiology and Medicine for Shinya Yamanaka and Sir John Gurdon, there is an explosion of medical attention to induced pluripotent stem cells (iPS) and reprogramming technology. When iPS is considered to be highly likely to open a new era in cell therapy and regenerative medicine, iPS-based cell therapy is clinically pre-clinical to bear the brunt of safety-related issues. In this review, we outline preclinical studies of iPS-derived neural stem / progenitor cells on spinal cord injury (SCI) and their in vivo safety issues and attempt to discuss their clinical strategies.